Clinical Study

The Time Profile of Pentraxin 3 in Patients with Acute ST-Elevation Myocardial Infarction and Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention

Table 1

Baseline characteristics of the study populations.

AMI group ( )AP group ( )

Age, years59.5 (54, 67)63.5 (54, 71)
Female gender ( )51
Hypertension ( )74
Diabetes ( )22
Smokers ( )72
Previous AMI ( )02
Previous PCI ( )04
Previous ACB ( )02
SBP (mmHg)140 (120, 154)137 (128, 146)
DBP (mmHg)85 (81, 98)85 (75, 100)
TnT max. (ng/L)3.5 (2.0, 5.7)
Infarct size (MRI) (%)6.6 (3.5, 10.7)
EF (MRI) (%)57.5 (53.3, 66.3)
Symptom debut to PCI (min)145 (95, 410)
Leukocyte count at 12 h9.0 (7.8, 10.4)7.6 (5.6, 8.2)
Medication at discharge
 Aspirin ( )2010
 Clopidogrel ( )209
 ACE-I/AII antagonist ( )112
β blocker ( )186
 Statin ( )2010

Values are given as proportions or medians (25, 75 percentiles).
ACE-I: angiotensin-converting enzyme inhibitor. AII antagonist: angiotensin II receptor antagonist. β blocker: beta adrenergic receptor blocker. ACB: coronary bypass surgery.
DBP: diastolic blood pressure. EF: ejection fraction. PCI: percutaneous coronary intervention. SBP: systolic blood pressure. TnT: Troponin T.